Nanoscope presents optical gene delivery, OCT-guided electrophysiology platforms at ARVO annual meeting
Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of retinal diseases, is featuring multiple scientific presentations highlighting its groundbreaking research on optical gene delivery for vision restoration and OCT-guided electrophysiology platforms for characterization of retinal degeneration and assessment of efficacy of cell-gene therapy at the 2021 ARVO annual (virtual) meeting, May 1-7.
ARVO, the Association for Research in Vision and Ophthalmology, is the largest eye and vision research organization in the world with nearly 11,000 members in more than 75 countries.
Related Stories
Nanoscope s lead product is an optogenetic gene therapy, vMCO-010, that delivers light- sensitive Multi-Characteristics Opsin (MCO) into retinal cells to restore vision in patients with retinal degeneration. If successful, the optogenetic therapy would b
E-Mail
IMAGE: Left: OCT-guided Laser microirradiation platform for generation of retinal degeneration, gene delivery and physiological evaluation of retina function. Right: Expression of therapeutic MCO gene in specific retinal cells in laser-targeted. view more
Credit: Nanoscope Technologies LLC
ARLINGTON, TX (May 5, 2021) Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of retinal diseases, is featuring multiple scientific presentations highlighting its groundbreaking research on optical gene delivery for vision restoration and OCT-guided electrophysiology platforms for characterization of retinal degeneration and assessment of efficacy of cell-gene therapy at the 2021 ARVO annual (virtual) meeting, May 1-7.
ARVO, the Association for Research in Vision and Ophthalmology, is the largest eye and vision research organization in the world with nearly 11,000 members in more than 75 countries.